Retinitis pigmentosa: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• RPGR 2
• VEGF 0
• AMPK 0
• NRF2 0
• STAT3 0
• AKT 0
• APOE 0
• GLP-1 0
• HDAC 0
• PARP 0
• SGLT2 0
• TFEB 0
• TNF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Repurposed Drug Neuroprotective Nanocarriers for Targeting Retinal Diseases (RENASCENT)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2027. szept.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Next generation versatile and effective AAV-mediated large gene delivery (NextGeneTx)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 1 500 000 EUR· until 2030. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases (ProgRet)

  Universiteit Gent· Gent, Belgium· EU contribution 2 626 200 EUR· until 2027. dec.· 10 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Targeting RNA as an approach for treating retinal disease (RETORNA)

  Fundacion Universidad Catolica de Valencia San Vicente Martir· Valencia, Spanyolország· EU contribution 2 568 426 EUR· until 2027. jan.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon 2020) · ERC-COG

  A unified drug discovery platform for protein misfolding diseases (ProMiDis)

  Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk· Vari-Athens, Görögország· EU contribution 1 972 000 EUR· until 2027. febr.

6 of 6 running projects, newest first. Listed amounts together: 9,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 1
• Organoids 11
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 7
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 19
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 9
• Magnetic Resonance Imaging 3
• Machine Learning 1
• Deep Learning 2
• Cohort Studies 5
• Genome-Wide Association Study 5

• Identification of a Duplication in the RP17 Locus in an Individual With Pathogenic CEP290 Variants: Implications for RP17 Variant Classification.

  Invest Ophthalmol Vis Sci, 2026. aug.

• Subretinal injection in the USH1CR31∗ pig model leads to chorioretinal atrophy that limits evaluation of efficacy of an AAV-mediated gene therapy.

  Exp Eye Res, 2026. júl.

• PRCD-associated retinitis pigmentosa in dogs and humans.

  Exp Eye Res, 2026. máj.

• Crosstalk Between R-Loops, RNA/DNA Modifications, and Cell Death Dynamics in Canine Models of Retinitis Pigmentosa.

  Invest Ophthalmol Vis Sci, 2026. febr.

• Presynaptic Changes in Mouse Rod Photoreceptors During Early Retinitis Pigmentosa.

  Invest Ophthalmol Vis Sci, 2025. dec.

• Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa.

  Free Radic Biol Med, 2011. júl.

• Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation.

  PLoS One, 2011. jún.

• Time course of auditory impairment in mice lacking the electroneutral sodium bicarbonate cotransporter NBC3 (slc4a7).

  Brain Res Dev Brain Res, 2005. szept.

• Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells.

  Ann Neurol, 2004. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.